Tim F Greten

Summary

Affiliation: Hannover Medical School
Country: Germany

Publications

  1. pmc Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells
    Sonja Obermann
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Immunology 122:90-7. 2007
  2. doi request reprint [Hepatocellular carcinoma - diagnosis and treatment]
    T F Greten
    Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Dtsch Med Wochenschr 133:1907-10. 2008
  3. ncbi request reprint [Molecular therapy for HCC?]
    T F Greten
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 44:205-6. 2006
  4. pmc Molecular therapy for the treatment of hepatocellular carcinoma
    T F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Center for Internal Medicine, Medical School of Hannover, Hannover, Germany
    Br J Cancer 100:19-23. 2009
  5. doi request reprint Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, 30625 Hannover, Germany
    J Immunother 33:211-8. 2010
  6. ncbi request reprint Immunotherapy of HCC
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Germany, Carl Neuberg Str 1, 30625 Hannover, Germany
    Rev Recent Clin Trials 3:31-9. 2008
  7. ncbi request reprint Immunotherapy of hepatocellular carcinoma
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany
    J Hepatol 45:868-78. 2006
  8. ncbi request reprint [Treatment of hepatocellular carcinoma]
    T F Greten
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 44:43-9. 2006
  9. doi request reprint [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC]
    T F Greten
    Klinik fur Gastroenterologie, Hepatologie, Endokrinologie, Medizinische Hochschule Hannover, Hannover
    Z Gastroenterol 47:55-60. 2009
  10. ncbi request reprint CD40 in hepatocellular carcinoma: relevant or not?
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Pasteurallee 5, 30655 Hannover, Germany
    Eur J Gastroenterol Hepatol 15:113-4. 2003

Detail Information

Publications43

  1. pmc Peptide-beta2-microglobulin-major histocompatibility complex expressing cells are potent antigen-presenting cells that can generate specific T cells
    Sonja Obermann
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Immunology 122:90-7. 2007
    ..The use of single-chain aAPC represent a promising option for the generation of antigen-specific CD8(+) T cells, which could be used for adoptive T-cell therapy...
  2. doi request reprint [Hepatocellular carcinoma - diagnosis and treatment]
    T F Greten
    Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Dtsch Med Wochenschr 133:1907-10. 2008
  3. ncbi request reprint [Molecular therapy for HCC?]
    T F Greten
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 44:205-6. 2006
  4. pmc Molecular therapy for the treatment of hepatocellular carcinoma
    T F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Center for Internal Medicine, Medical School of Hannover, Hannover, Germany
    Br J Cancer 100:19-23. 2009
    ..In this review we summarise this data and point to a number of new compounds, which are currently being tested and can potentially broaden our therapeutic arsenal even further...
  5. doi request reprint Low-dose cyclophosphamide treatment impairs regulatory T cells and unmasks AFP-specific CD4+ T-cell responses in patients with advanced HCC
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, 30625 Hannover, Germany
    J Immunother 33:211-8. 2010
    ....
  6. ncbi request reprint Immunotherapy of HCC
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Germany, Carl Neuberg Str 1, 30625 Hannover, Germany
    Rev Recent Clin Trials 3:31-9. 2008
    ..Although only a limited number of patients have been enrolled in most trials so far, results from these studies clearly suggest that immunotherapy is safe in HCC patients. Here, we review recent immunotherapy trials in HCC...
  7. ncbi request reprint Immunotherapy of hepatocellular carcinoma
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Germany
    J Hepatol 45:868-78. 2006
  8. ncbi request reprint [Treatment of hepatocellular carcinoma]
    T F Greten
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 44:43-9. 2006
    ..These treatments can improve (tumour-free) survival and in a few cases even cure the patient...
  9. doi request reprint [Sorafenib for the treatment of HCC--the beginning of a new era in the treatment of HCC]
    T F Greten
    Klinik fur Gastroenterologie, Hepatologie, Endokrinologie, Medizinische Hochschule Hannover, Hannover
    Z Gastroenterol 47:55-60. 2009
    ..We summarize recent results on the molecular therapy for HCC and discuss how these can be efficiently tested in patients with HCC...
  10. ncbi request reprint CD40 in hepatocellular carcinoma: relevant or not?
    Tim F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Pasteurallee 5, 30655 Hannover, Germany
    Eur J Gastroenterol Hepatol 15:113-4. 2003
    ....
  11. ncbi request reprint Peptide-beta2-microglobulin-MHC fusion molecules bind antigen-specific T cells and can be used for multivalent MHC-Ig complexes
    Tim F Greten
    Abteilung Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, FZ Oststadt, Raum 310, Pasteurallee 5, Germany
    J Immunol Methods 271:125-35. 2002
    ..These molecules bind antigen-specific T cells with high specificity and sensitivity, therefore, providing a valuable tool for detection as well as enrichment of antigen-specific T cells...
  12. pmc Survival rate in patients with hepatocellular carcinoma: a retrospective analysis of 389 patients
    T F Greten
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, Carl Neuberg Str 1, Hannover 30625, Germany
    Br J Cancer 92:1862-8. 2005
    ..This study will help to estimate survival rates for patients with HCC according to their clinical status at diagnosis and the treatments received...
  13. pmc Increase in frequency of myeloid-derived suppressor cells in mice with spontaneous pancreatic carcinoma
    Fei Zhao
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Immunology 128:141-9. 2009
    ..These results highlight the importance of blocking these suppressor mechanisms early in the disease in developing immunotherapy protocols...
  14. ncbi request reprint CD49d is a new marker for distinct myeloid-derived suppressor cell subpopulations in mice
    Lydia A Haile
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover, Germany
    J Immunol 185:203-10. 2010
    ..We suggest that CD49d can be used as an alternative marker for Gr-1 to differentiate between the subpopulations of MDSCs together with CD11b, which will ultimately help in understanding the mechanisms of immune suppression by MDSCs...
  15. ncbi request reprint Direct ex vivo analysis of dendritic cells in patients with hepatocellular carcinoma
    Lars A Ormandy
    Department of Gastroenterology, Hepatology und Endocrinology, Medizinische Hochschule Hannover, Carl Neuberg Str 1, 30625 Hannover, Germany
    World J Gastroenterol 12:3275-82. 2006
    ..To analyze the phenotype and function of dendritic cells (DC) from patients with hepatocellular carcinoma (HCC) in order to understand their role in this disease...
  16. doi request reprint Immune responses in hepatocellular carcinoma
    Firouzeh Korangy
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    Dig Dis 28:150-4. 2010
    ..We propose that targeting suppressor cells either alone or in combination with conventional immunotherapy should be further evaluated in HCC patients...
  17. doi request reprint Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway
    Lydia A Haile
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Gastroenterology 135:871-81, 881.e1-5. 2008
    ..Here, for the first time, we have identified and analyzed their role in inflammatory bowel disease (IBD)...
  18. doi request reprint Myeloid derived suppressor cells inhibit natural killer cells in patients with hepatocellular carcinoma via the NKp30 receptor
    Bastian Hoechst
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School, Hannover, Germany
    Hepatology 50:799-807. 2009
    ..These findings have important implications when designing immunotherapy protocols...
  19. doi request reprint A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+)Foxp3(+) T cells
    Bastian Hoechst
    Medizinische Hochschule Hannover, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany
    Gastroenterology 135:234-43. 2008
    ..In this study, we have investigated the frequency and function of a new population of MDSC denoted here as CD14(+)HLA-DR(-/low) in HCC patients. We have also identified a novel, MDSC-mediated immune regulatory pathway in these patients...
  20. ncbi request reprint Spontaneous tumor-specific humoral and cellular immune responses to NY-ESO-1 in hepatocellular carcinoma
    Firouzeh Korangy
    Department of Gastroenterology, Hepatology and Endocrinology, Clinic of Visceral and Transplantation Surgery, Medizinische Hochschule Hannover, Hannover, Germany
    Clin Cancer Res 10:4332-41. 2004
    ..NY-ESO-1, a member of the cancer testis antigen family, is one possible candidate for a tumor-specific antigen in HCC. The aim of this study was to show the relevance of NY-ESO-1 in hepatocellular carcinoma...
  21. ncbi request reprint Necrotic tumor cell death in vivo impairs tumor-specific immune responses
    Jaba Gamrekelashvili
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Immunol 178:1573-80. 2007
    ..These observations have not only fundamental importance for the development of immunotherapy protocols but also help to understand the underlying mechanism of in vivo immune responses to tumor cell death...
  22. pmc Identification of a novel murine pancreatic tumour antigen, which elicits antibody responses in patients with pancreatic carcinoma
    Fei Zhao
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Immunology 128:134-40. 2009
    ..Reverse transcriptase-polymerase chain reaction analysis showed Tankyrase-2 expression in human pancreatic tumour. These findings show the relevance of spontaneous murine tumour models for the identification of human tumour antigens...
  23. pmc A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
    Tim F Greten
    Department of Gastroenterology, Hannover Medical School, Carl Neuberg Strasse 1, 30625 Hannover, Germany
    BMC Cancer 10:209. 2010
    ..In this open label, single arm clinical trial, we analyzed the effect of a low dose cyclophosphamide treatment in combination with a telomerase peptide (GV1001) vaccination in patients with advanced HCC...
  24. ncbi request reprint Immunotherapy of hepatocellular carcinoma
    Firouzeh Korangy
    Hannover Medical School, Hannover, Germany
    Expert Rev Gastroenterol Hepatol 4:345-53. 2010
    ..However, we propose that any of these immunotherapeutic approaches needs to be combined with a therapy specifically targeting suppressor cells in HCC...
  25. pmc S100A9 a new marker for monocytic human myeloid-derived suppressor cells
    Fei Zhao
    National Institutes of Health, National Cancer Institute, Medical Oncology Branch, Bethesda, MD 20892, USA
    Immunology 136:176-83. 2012
    ..We propose S100 proteins as useful markers for the analysis and further characterization of human MDSC...
  26. ncbi request reprint Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma
    Lars A Ormandy
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Cancer Res 65:2457-64. 2005
    ..Our data suggest that the increase in frequency of regulatory T cells might play a role in modulation of the immune response against HCC and could be important in design of immunotherapeutic approaches...
  27. ncbi request reprint Lipopolysaccharide-mediated mast cell activation induces IFN-gamma secretion by NK cells
    Katja Vosskuhl
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    J Immunol 185:119-25. 2010
    ..This interaction might play an important role in innate immune defense, as it is dependent on the presence of stimulators relevant in innate immune responses...
  28. ncbi request reprint Apoptotic, but not necrotic, tumor cell vaccines induce a potent immune response in vivo
    Stephan R Scheffer
    Department of Gastroenterology, Medizinische Hochschule Hannover, Hannover, Germany
    Int J Cancer 103:205-11. 2003
    ..In contrast, necrotic cell vaccines attracted a strong local macrophage response. Our data clearly demonstrate that only apoptotic tumor cell vaccines induce a potent antitumor immune response...
  29. doi request reprint Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells
    Bastian Hoechst
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Blood 117:6532-41. 2011
    ..The balance between these 2 subsets can impact the outcome of immune reaction from inflammation to tolerance...
  30. ncbi request reprint Genetically induced pancreatic adenocarcinoma is highly immunogenic and causes spontaneous tumor-specific immune responses
    Annette I Garbe
    Department of Gastroenterology, Hepatology, and Endocrinology, Medizinische Hochschule Hannover, Hannover, Germany
    Cancer Res 66:508-16. 2006
    ..c. injected tumors and spontaneous tumors showed significant differences in tumor-specific immune responses, which will help in improving current immune-based cancer therapies against adenocarcinoma of the pancreas...
  31. ncbi request reprint Epidemiological trends in incidence and mortality of hepatobiliary cancers in Germany
    Thomas von Hahn
    Department of Gastroenterology, Hepatology and Endocrinology, Medizinische Hochschule, Hannover Medical School, Hannover, Germany
    Scand J Gastroenterol 46:1092-8. 2011
    ..We aimed to provide epidemiological data on recent trends in liver-related mortality, specifically mortality from hepatobiliary malignancies, in Germany...
  32. ncbi request reprint [CMV-enterocolitis as a cause for repeated intestinal intussusceptions in an adult patient after liver transplantation?]
    S Pischke
    Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Z Gastroenterol 48:688-92. 2010
    ..Whenever possible a PCR for CMV in colon biopsies should be carried out to detect an intestinal CMV infection because as shown in our case results for immunohistopathology and CMV pp65 can be negative despite a chronic infection...
  33. ncbi request reprint Molecular therapy of pancreatic cancer
    R R Plentz
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Minerva Endocrinol 35:27-33. 2010
    ..However, our review presents the current developments of molecular therapies, supports the translational PDAC research and encourage you to take part in further clinical studies...
  34. ncbi request reprint Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial
    T D Kirchhoff
    Department of Diagnostic Radiology, Hannover Medical School, OE 8220, D 30625 Hannover, and Department of Radiology, University Hospital, Bonn, Germany
    Eur J Surg Oncol 32:201-7. 2006
    ..In a randomised phase II trial TACO was compared to transarterial chemoperfusion without DSM (TACP)...
  35. pmc The diagnosis and treatment of hepatocellular carcinoma
    Nisar P Malek
    Department of Medicine, Eberhard Karls University of Tubingen, Department of Gastroenterology, Hepatology and Endocrinology, Hanover Medical School, Center for Cancer Research, NIH, Bethesda, USA
    Dtsch Arztebl Int 111:101-6. 2014
    ..The incidence of hepatocellular carcinoma (HCC) has continued to rise in recent years. This increase has been attributed to alcohol-induced liverdiseases, metabolic syndrome, and the rising number of hepatitis B and C viral infections...
  36. pmc Regulation of accumulation and function of myeloid derived suppressor cells in different murine models of hepatocellular carcinoma
    Tamar Kapanadze
    Gastrointestinal Malignancy Section, Medical Oncology Branch, National Cancer Institute, Bethesda, USA Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Hepatol 59:1007-13. 2013
    ..The aim of this study was to examine the biology of MDSC in murine HCC models and to identify a model, which mimics the human disease...
  37. ncbi request reprint Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival
    Timm D Kirchhoff
    Department of Diagnostic Radiology, Hannover Medical School, Hannover, Germany
    Hepatobiliary Pancreat Dis Int 6:259-66. 2007
    ..A moderate embolizing approach was chosen using a combination of degradable starch microspheres (DSM) and iodized oil (Lipiodol) in order to combine anti-tumoral efficiency and low toxicity...
  38. doi request reprint Fulminant hepatic failure due to chemotherapy-induced hepatitis B reactivation: role of rituximab
    M A Stange
    Department of Gastroenterology, Hepatology and Endocrinology, Medical School Hannover, Hannover, Germany
    Z Gastroenterol 48:258-63. 2010
    ..Pre-emptive antiviral treatments should be administered since delayed antiviral treatment is frequently unable to prevent liver failure...
  39. doi request reprint Critical appraisal of clinical practice guidelines for diagnosis and treatment of hepatocellular carcinoma
    Sebastian Schmidt
    Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany
    J Gastroenterol Hepatol 26:1779-86. 2011
    ....
  40. doi request reprint [Suspicion of a newly appearing hypertrophic obstructive cardiomyopathy in a patient treated for hepatocellular carcinoma]
    S Ciesek
    Klinik fur Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover
    Dtsch Med Wochenschr 133:2209-12. 2008
    ..A 42-year-old women presented with shortness of breath, tachycardia and weakness to our department. Five years ago she had been diagnosed with hepatocellular carcinoma for which an extended hemihepatectomy had been performed...
  41. pmc Development and use of multimeric major histocompatibility complex molecules
    Tim F Greten
    Department of Gastroenterology and Hepatology, Medizinische Hochschule Hannover, 30655 Hannover, Germany
    Clin Diagn Lab Immunol 9:216-20. 2002
  42. doi request reprint Sorafenib in advanced hepatocellular carcinoma
    Josep M Llovet
    Barcelona Clinic Liver Cancer Group, Institut d Investigacions Biomediques August Pi i Sunyer, Centro de Investigaciones en Red de Enfermedades Hepáticas y Digestivas Hospital Clínic Barcelona, Barcelona
    N Engl J Med 359:378-90. 2008
    ..A preliminary study suggested that sorafenib, an oral multikinase inhibitor of the vascular endothelial growth factor receptor, the platelet-derived growth factor receptor, and Raf may be effective in hepatocellular carcinoma...
  43. ncbi request reprint Tumor-associated gene expression in disseminated tumor cells correlates with disease progression and tumor stage in colorectal cancer
    Veit Zieglschmid
    AdnaGen AG, Ostpassage 7, D 30853 Langenhagen, Germany
    Anticancer Res 27:1823-32. 2007
    ..Detection of DTC and expression of tumor-associated genes might be of clinical value with respect to individual patient prognosis, monitoring of therapy and as a surrogate tumor staging parameter...